Royalty Report: Agriculture, Forestry and Fishing, Drugs – Collection: 290208

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 14

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 14

Primary Industries

  • Agriculture
  • Forestry and Fishing
  • Drugs
  • Therapeutic
  • Genome
  • cardiac
  • Molecular
  • Proteins
  • Technical Know How
  • Biotechnologys
  • Biotechnology
  • Nutraceutical
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 290208

License Grant
Licensor hereby grants Netherlands Licensee and its Affiliates a non-exclusive, worldwide, non-terminable license with the right to grant sublicenses, under the Licensor Patent Rights (other than the Licensor Antibody Patent Rights), for all uses in the Field, including, without limitation, to make, have made, use, sell, offer for sale, import and export Licensee Licensed Products in the Field. Such license shall not expire until the earlier of (i) the expiration of the last to expire Valid Claim of the Licensor Patent Rights other than the Licensor Antibody Patent Rights or (ii) termination of this Agreement of this Agreement.
License Property
Licensee Licensed Product shall mean any product, the manufacture, use, or sale of which would, absent the licenses granted to Licensee hereunder, infringe one or more Valid Claims of the Licensor Patent Rights.

Licensor Patent Rights shall mean: (a) USSN 07/938,322 entitled 'Transgenic Animals Secreting Desired Proteins into Milk', including, without limitation, EP-973031124, and any foreign counterpart applications, together with any and all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and (b) all related divisionals,  continuations, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues or renewals, of the foregoing; and (c) the Licensor Antibody Patent Rights.

Licensor Antibody Patent Rights shall mean (a) U.S. Patent Nos. 5,827,690 and 5,849,992 both entitled 'Transgenic Production of Antibodies in Milk', and all U.S. patent applications and any foreign counterpart applications, and future issued patents including all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and all related divisionals, continuations, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues or renewals, of the foregoing pertaining to the production of antibodies in the milk of transgenic mammals.

Biopharmaceutical shall mean any medicinal drug, therapeutic, vaccine or any medically useful composition whose origin, synthesis, or manufacture involves the use of microorganisms, recombinant animals (including, without limitation, chimeric or transgenic animals), nuclear transfer, microinjection, or cell culture techniques.

HSA shall mean human serum albumin.

Field of Use
This agreement pertains to the agricultural Industry.

Field shall mean: (a) the Cattle Field; (b) the Goat Field; (c) the production, use and/or sale of transgenic or chimeric mice, rabbits, pigs, and/or sheep (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric animals; and (d) the use in any transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep of a nucleic acid construct useful in the production of a system that includes the use of a recombinant casein promoter sequence, which permits a female transgenic or chimeric animal to produce a desired Biopharmaceutical in the milk (or any fraction thereof) of such a transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep
during lactation.

Goat Field shall mean the production, use and/or sale of transgenic or chimeric goats (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction
thereof) secreted from such transgenic or chimeric goats.

Cattle Field shall mean the production, use and/or sale of transgenic or chimeric cattle (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric cattle, including, without limitation, the production of hSA.

IPSCIO Record ID: 289146

License Grant
The Netherlands Licensor hereby grants Licensee and its Affiliates a non-exclusive, worldwide, non-terminable license with the right to grant sublicenses, under the Licensor Patent Rights for all uses in the Field, including without limitation, to make, have made, use, sell, offer for sale, import and export Licensee Licensed Products in the Field. Such license shall not expire until the last to expire Valid Claim of the Licensor Patent Rights.
License Property
Licensor Patent Rights shall mean: (a) all patents and patent applications as set forth hereto and incorporated herein, together with any and all patents that have issued or in the case of applications heretofore filed, in the future issue therefrom or whose priority date is based thereon; and (b) all related divisionals, continuations, continuations-in-part, national stage applications or patents filed under the Patent Cooperation Treaty of 1978, reissues, renewals, extensions or additions to any such patents and patent applications; but shall specifically exclude the Biogen Patent Rights and the ProBio Patent Rights.
5,304,489 – DNA sequences to target proteins to the mammary gland for efficient secretion
5,565,362 – DNA sequences to target proteins to the mammary gland for efficient secretion
5,633,076 – Method of producing a transgenic bovine or transgenic bovine embryo

Licensee Licensed Product shall mean any product, the manufacture, use, or sale of which would, absent the licenses granted to Licensee hereunder, infringe one or more Valid Claims of the Licensor Patent Rights.

Biopharmaceutical shall mean any medicinal drug, therapeutic, vaccine or any medically useful composition whose origin, synthesis, or manufacture involves the use of microorganisms, recombinant animals (including, without limitation, chimeric or transgenic animals), nuclear transfer, microinjection, or cell culture techniques.

HSA shall mean human serum albumin.

Field of Use
Field shall mean: (a) the Cattle Field; (b) the Goat Field; (c) the production, use and/or sale of transgenic or chimeric mice, rabbits, pigs, and/or sheep (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric animals; and (d) the use in any transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep of a nucleic acid construct useful in the production of a system that includes the use of a recombinant casein promoter sequence, which permits a female transgenic or chimeric animal to produce a desired Biopharmaceutical in the milk (or any fraction thereof) of such a transgenic or chimeric cattle, goats, mice, rabbits, pigs, and/or sheep during lactation.

Goat Field shall mean the production, use and/or sale of transgenic or chimeric goats (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric goats.

Cattle Field shall mean the production, use and/or sale of transgenic or chimeric cattle (including their respective embryos, gametes and/or progeny) for the production of Biopharmaceuticals in the milk (including any fraction thereof) secreted from such transgenic or chimeric cattle, including, without limitation, the production of hSA.

IPSCIO Record ID: 274943

License Grant
Licensor hereby grants Licensee a worldwide, royalty-bearing, non-terminable, non-exclusive license under the Licensor Technology and Licensor Patents to make, have made, use, and sell Licensee Products in the Licensee Field. Such license will not expire until the expiration of the last to expire valid claim of the Licensor Patents.
License Property
Licensee Products shall mean any product, the manufacture, use or sale of which utilizes any Licensor Technology or infringes a valid claim of any
Licensor Patent.

Licensor Patents shall mean the patent and patent applications listed in this Agreement and any patents issuing therefrom, together with any extensions, reissues, renewals, divisions, continuations or continuations-in-part thereof which Licensor presently or hereafter owns, solely with respect to the production of proteins in the milk of transgenic animals. Notwithstanding the foregoing, in the event that any claim of the Licensor Patents are invalidated as a result of a US patent interference with any claims of the Rosen Patent, then the corresponding claims from the Rosen Patent shall be substituted herein. As used herein, Rosen Patent shall mean the Licensor Patent designated as U.S. Patent No. 5,304,489 and all continuations, continuations-in-part and divisional patent applications thereof and related thereto, all counterpart foreign applications of the foregoing, and any patents issuing thereon.

Patents:
5,304,489 – DNA sequences to target proteins to the mammary gland for efficient secretion
US 4,837,316 – Alkylamide derivatives with H.sub.2 -receptor antagonistic and cytoprotective action
US 5,750,172 – Transgenic non human mammal milk

Licensor Technology shall mean the materials owned or controlled by Licensor which are useful in the Licensee Field and which are listed:
Casein Expression system
Human Serum Albumin
Basic Research Tools

Field of Use
Licensee Field shall mean the production of any protein in the milk of any transgenic animal, except the commercial production of urokinase in the milk of any animal and the commercial production of alpha-amalyse, alpha-lactalbumin, desaturase, lactase, lactoferrin, lactoperoxidase, lysozyme and bile-salt stimulated lipase in the milk of cattle. In addition, Licensee agrees it will not commercially produce Factor VIII in the milk of any animal without first obtaining the written permission of Licensor.

IPSCIO Record ID: 238999

License Grant
For the Licensor Platform Rights,  Licensor grants to an exclusive worldwide, license, with the right to grant sublicenses, under the Licensor Platform Rights, Licensed Improvements and Licensors rights in the Joint Platform Improvements to make, have made, use, sell, offer for sale, import and export Licensed Products in the Field.

For the Cattle Rights, Licensor grants a non-exclusive, worldwide license, with the right to grant sublicenses, under the Cattle Patent Rights to make, have made, use, sell, offer for sale, import and export Cattle Products in the Field.

For the Promoter Rights, Licensor grants a non-exclusive, worldwide license, without the right to grant sublicenses, under the Promoter Rights to make, have made, use and sell Promoter Products in the Field.

License Property
The Licensor has substantial programs and interest in the development of transgenic animals for the production of proteins, peptides and polypeptides in the milk of such animals for use as Biopharmaceuticals.

The licensed patents are for Cattle Patent Rights, Platform Patent Rights, rhSA Patent Rights, and, Promoter Patent Rights.

Recombinant Human Serum Albumin (rhSA) is a plasma protein that is principally responsible for maintaining the osmotic pressure in the vascular system, as well as plasma volume and the balance of fluids in blood.

Field of Use
Field shall mean the development, manufacture, use, marketing, sale and overall commercialization of rhSA or any Biopharmaceutical derived from or utilizing rhSA (but excluding fusion proteins) for therapeutic and non-therapeutic uses.

IPSCIO Record ID: 256191

License Grant
The University grants the sole and exclusive right and license to make, use, offer to sell, sell, import and sublicense Licensed Patents within the Field of Use and in the Licensed Territory for the Term.
License Property
The patents include, but are not limited to:
—  Production of Transgenic Early Embryonic Chicken Cells and Chimeric Chickens Using EGFP and Puromycin Selection Methods,
—  Transgenesis of Early Embryonic Cells,
—  Avians that Produce Eggs Containing Exogenous Proteins,
—  Exogenous Proteins Expressed in Avians and Their Eggs,
—  Novel Vectors in Avian Transgenesis,
—  Vectors Comprising a Magnum-Specific Promoter for Avian Transgenesis, and,
—  Method for Manipulating Eggs
Field of Use
The Field of Use means avian trans genesis as it may relate to introduction of DNA sequences in any avian species expression of autologous and allogeneic molecules in any avian species, use of avians and their eggs as bioreactor] and improved poultry production genetics.

IPSCIO Record ID: 121485

License Grant
In general, Norwegian Licensor shall supply Licensee with Products, and shall put its Technology related to pig breeding and reproduction at  Licensees disposal; Licensee shall Exploit Licensors Products and Technology in its crossbreeding program for the purpose of producing Derived Products to be sold in the Territory.

Hence Licensor grants to Licensee the non-exclusive distributorship for its Derived Products in the Territory.

License Property
Derived Products shall mean Genetic Materials directly or indirectly derived from the Products, to be Exploited by Licensee in the Territory.

Genetic Materials shall mean Breeding Pigs, their semen and/or their embryos.

Breeding Pig shall mean a male or female pig destined for the production of other pigs.

Technology shall mean Licensors know-how and methodology related to pig breeding and reproduction, including its updating, pat at Licensees disposal for the purpose of this Agreement.

Field of Use
This agreement pertains to the agriculture industry relating to animals.

IPSCIO Record ID: 291180

License Grant
Licensor grants to Licensee an exclusive license in the Field and in the Territory to practice and use the Licensor Technology and to develop, make, have made, use, sell, offer to sell, and import Licensed Products.
License Property
Licensor Technology means Licensor Patents, Licensor Confidential Information, Licensor Developments, and Licensor know-how, materials, information and methods (whether developed by or on behalf of Licensor or acquired from a Third Party), including, but not limited to methods for controlling plant senescence involving altering the expression of plant genes and their cognate expressed proteins that are induced during or coincident with the onset of senescence.

Licensed Product means any product containing Licensor Technology within the Field.

Licensor Patents means (i) all U.S. and foreign patent applications owned or controlled by or licensed to Licensor or its Affiliates, pending as of the Effective Date or at any time thereafter during the term hereof, pertaining to controlling senescence, including original applications, provisionals, divisions, continuations, continuations in part, extensions, PCT applications, renewals, reissues, or reexamination applications or supplemental prosecution certificates, including, but not limited to, all applications listed; (ii) all U.S. and foreign patents that have issued or will issue from any application identified hereof; and (iii) all U.S. and foreign applications that claim priority in any way from any application or patent identified in (i) or (ii).
6,538,182 – DNA encoding a plant deoxyhypusine synthase, a plant eukaryotic initiation factor 5A, transgenic plants and a method for controlling senescence programmed and cell death in plants
7,033,833 – Polynucleotides encoding carnation senescense-induced EIF-5A
6,900,368 – Tomato antisense deoxyhypusine synthase molecule and method of inhibiting deoxyhypusine synthase expression in plants

Field of Use
Field means all trees cultivated, harvested, or produced for any purpose (other than those grown for the purpose of edible fruit and nut production), including all derivative products resulting from such trees regardless of end use, whether transgenic or otherwise.

IPSCIO Record ID: 230814

License Grant
The original research collaboration agreement was entered to discover and develop new Biomolecules and Products based on such Biomolecules utilizing the technology licensed by the Swiss Licensee to Licensor as well as Licensors technology and expertise.

This agreement is to provide for, among other things, the transfer of certain projects undertaken under the Licensees Affiliates Agreement and the Joint Venture Agreement to the Research Collaboration Agreement, as amended by this Amendment.

The Parties desire to amend the Research Collaboration Agreement in accordance with the Transition Agreement to provide for, among other things, the transfer of certain projects undertaken under the Affiliates Agreement and the Joint Venture Agreement to the Research Collaboration Agreement, as amended by this Amendment.

With this amendment, Licensor grants the Swiss Licensee the exclusive option to include the Affiliates Animal Feed Field in the Licensees Exclusive Field under the terms of the Research Collaboration Agreement, as amended.

Licensor grants an exclusive option to develop and commercialize the product known as D45 and all derivatives thereof on a sole and exclusive basis in the Licensees Exclusive Field.

License Property
Animal Feed Field means the use of Biomolecules for feed applications to alter, modify or improve feed conversion and/or animal nutrition, but excluding all vaccines and therapeutic applications.

Approved Affiliates Research Projects means the projects in existence under the Affiliates Agreement known as Coarse Grain Glucanase, Coarse Grain Amalase and Coarse Grain Protease.

All Biomolecules developed or invented under the Affiliates Agreement and Joint Venture Agreement shall be made available for research, development and commercialization and shall be treated as Biomolecules in all respects, under the Research Collaboration Agreement, as amended by this Amendment, including, without limitation:
(a) the Pre-Amendment Inventions;
(b) the Post-Amendment Inventions;
(c) all of such Biomolecules tested under the criteria set forth in the project plans to establish TB or COB status under the Affiliates Agreement as of the Effective Date but that did not meet the applicable Minimum Activity Level ( as such term is defined in the Affiliates Agreement); and·
(d) all of such Biomolecules for which specific gene sequence data is not available as of the date of execution of this Amendment but whose activity was detected in the applicable screen set forth in the applicable project plan under the Affiliates Agreement.

Field of Use
Licensors Field of Exploitation means products based on microbially-derived Biomolecules, not produced in Plants, for use in the pulp and paper industry solely for deinking, pitch control, papermachine boilout cleaning, deposit control, fiber strengthening, and reduction of bleaching chemicals.

IPSCIO Record ID: 291161

License Grant
Licensor hereby grants to Licensee Therapeutics, Inc. an exclusive, non-assignable license to its rights in and to the GMO Technology to make, use, have made and sell products using or incorporating the GMO Technology, any patents or patent applications relating thereto and all related know-how.
License Property
GMO Technology is a new invention developed.

GMO Technology means a Megasort based assay of a transgenic organism directed to scan the entire genome of the organism to identify and characterize any foreign DNA sequences integrated in that transgenic organism as compared to an isogenic untransformed organism, which shall have such performance characteristics as identified from time to time by the JRC, as well as any additional technology arising out of performance under the GMO Development Plan.

GMO Development Plan means the science plan agreed upon by Licensor and approved by Licensee relating to the joint development of the GMO Technology, pursuant to which the GMO Technology will be developed within six to twelve months from the date of execution of this Amendment.

Field of Use
This agreement pertains to the agriculture industry.

IPSCIO Record ID: 257471

License Grant
The University grants an Exclusive, sublicensable license, in the Field, under the Licensed Patent Rights and any other Technology Rights, to research, develop, make, have made, import, have imported, use, have used, sell, have sold, offer for sale, have offered for sale, and otherwise exploit Licensed Products in the Territory and in the Field.
License Property
Confidential Technology means the detailed culturing, e.g., fermentation, protocols related to the Licensed Product;  the specific location in North America where the bacterial strain for the Licensed Product was originally isolated; detailed protocols, dosage, etc., used for killing the cells by either e-beaming or gamma ionizing radiation; and detailed protocols for combining supernatant with cells to achieve higher dreissenid mortality than would be achieved by just cells alone.

The patent is for A Method for Controlling Dreissena Species.

Field of Use
The Field means applications or uses as a pesticide.

IPSCIO Record ID: 4297

License Grant
We entered into a development and commercialization agreement with Licensee, which was superseded by an exclusive development and license agreement, pursuant to which each party exclusively licensed to the other certain patent rights and technology and pursuant to which we agreed to provide certain related services.

Under the agreement, we agreed by September 1, 2000, to produce at least 20 cloned hSA cows (cows produced with our technology that are transfected with a GTC recombinant DNA construct and contain the hSA transgene and express hSA in their milk for the purpose of transgenic production of milk products.)

License Property
Under the agreement, we license to Licensee certain patent rights and know-how useful to the cloning of animals for all purposes for the production of biopharmaceutical agents in milk, including, but not limited, proteins, peptides and polypeptides for pharmaceutical, neutraceutical or other use.

IPSCIO Record ID: 238998

License Grant
Licensor will:
– Design, build and validate dedicated housing, milking and clarification facilities and equipment;
– Scale-up and transfer the milk clarification process for production of commercial quantities of rhAFP;
– Scale-up_ the female Transgenic Goat herd; and
– Produce commercial quantities of rhAFP in Clarified Milk according to Licensees commercial product projections as provided by Licensee to Licensor.

Licensor grants a perpetual, nonexclusive license to practice the Clarification Technology within the Field of Interest.

The Parties grant to each other, license to practice any Invention pertaining to the Field of Interest including without limitation Intellectual Property related to the production of rhAFP from Clarified Milk, assays and/or analytical techniques useful in the measurement or characterization of rhAFP in Clarified Milk or the purification of rhAFP from Clarified Milk developed pursuant to this Agreement, with aright to grant sublicenses.

License Property
Clarified Milk shall mean the milk of Transgenic Goats that contains rhAFP and that has been processed to remove particulates, excess casein micelles and lipid allowing further processing to recover rhAFP.

rhAFP shall mean recombinant human non-glycosolated Alpha Fetoprotein.

Field of Use
The field of interest shall mean the production of rhAFP in a Clarified Milk product of a transgenic animal and/or the means to process that Clarified Mille into a form of rhAFP useful as a Biopharmaceutical.

The agreement is for the purpose of producing rhAFP in the milk of transgenic animals for Merrimacks use in pre-clinical studies, clinical trials and commercial distribution.

Licensee expects to initiate the first human clinical studies of MM-093 later this year. Initial studies will be designed to evaluate the safety of the protein in healthy volunteers. Once safety has been demonstrated, Licensee intends to undertake clinical studies in myasthenia gravis, multiple sclerosis and rheumatoid arthritis. Myasthenia gravis is an autoimmune disease of the voluntary muscles which affects more than 84,000 patients in the United States and Europe.

IPSCIO Record ID: 282872

License Grant
Licensor grants a world-wide, exclusive license under the Licensor Technology to make, have made, use, sell, offer for sale, and import Licensed Products and to provide Licensed Services, but excluding all uses of Licensed Products or Licensor Technology in the Plant Field and excluding all Plant Products, in each case solely in the Field and a world-wide, co-exclusive license under the Licensor Technology to make, have made, use, sell, offer for sale, and import Permitted Plant Products and to provide Permitted Plant Services, in each case solely in the Field.
License Property
Linensor has proprietary technology relating to, zmc finger proteins and their use to alter the genomes and/or protein expression capabilities of organisms and cells.

Active Supplied ZFN shall mean a Supplied ZFN having demonstrated ability to modify at least one allele of the applicable Target in a cell culture assay or other in vivo assay.

Licensed Product means any product the creation, development, manufacture, use, importation, sale or offer for sale of which, in the absence of the licenses granted in this Agreement, would infringe a Valid Claim or that incorporates Licensor Know-How, or any Licensed Service.

Supplied ZFN means nucleic acids encoding a single pair of zinc-finger protein nucleases directed against a Target.

ZFN Technology means technology relating to zinc finger proteins and their use to alter the genomes and/or protein expression capabilities of organisms and cells.

ZFP Product means a zinc-finger protein (including a zinc-finger transcription factor or a zinc-finger nuclease) or a nucleic acid encoding and capable of expressing such protein (for example, in a cell or tissue), and services in connection therewith.

Field of Use
Field means any use for research purposes. The Field shall exclude any Commercial Use of Licensed Products and any use of Licensed Products for human healthcare, including prophylaxis and diagnosis or animal healthcare including prophylaxis and diagnosis, collectively, the Excluded Fields.  

Plant Field means gene targeting and/or gene regulation using a ZFP Product to modify the genome of a plant cell, plant, or plant cell culture (in each case, whether constituting or derived from a vascular or non-vascular plant), or alter the nucleic acid or protein expression in a plant cell, plant, or plant cell culture. For the purpose of this Agreement, nonvascular plants shall include but not be limited to algae, moss, and fungi.

IPSCIO Record ID: 239155

License Grant
This agreement is a strategic alliance for the purpose of producing rhAFP in the milk of transgenic animals, and includes services and grants of rights, and, the commercial sale of  rhAFP Product to a person or entity or the grant of rights to sell or distribute its Transgenic rhAFP Product.

The Parties grant each other a non-exclusive license to practice any Invention pertaining to the Field of Interest including without limitation Intellectual Property related to the production of rhAFP from Clarified Milk, assays and/or analytical techniques useful in the measurement or characterization of rhAFP in Clarified Milk or the purification of rhAFP from Clarified Mille developed pursuant to this Agreement, with a right to grant sublicenses. Notwithstanding any provision herein to the contrary the breadth of such a license shall be only as it pertains to rhAFP.

Licensor grants to a perpetual, nonexclusive license to practice the Clarification Technology within the Field of Interest.

License Property
The property is the processes, technology and service for producing and distributing clarified goat milk containing recombinant human alpha fetoprotein.   Licensor is a leader in the development of therapeutic proteins in the milk of transgenic animals.
Field of Use
The field of interest shall mean the production of rhAFP in a Clarified Milk product of a transgenic animal and/or the means to process that Clarified Milk into a form of rhAFP useful as a Biopharmaceutical.  Licensee is a biotechnology company actively involved in the development of recombinant human alpha fetoprotein.

MM-093, Licensee's lead clinical product, is a recombinant version of human alpha-fetoprotein. Licenseeis conducting a Phase II study of MM-093 in patients with rheumatoid arthritis and is planning additional clinical studies.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.